Prof. Dr. Jens Huober
chief physician
Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019)
Untch M, Kühn T, Luftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching P, Kolberg-Liedtke C, Kolberg H, Thomssen C, Bauerfeind I, Braun M, Brucker S, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Harbeck N. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd 2019; 79:591-604.
Jun 14, 2019Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019)
Jun 14, 2019Geburtshilfe Frauenheilkd 2019; 79:591-604
Untch Michael, Kühn Thorsten, Luftner Diana, Maass Nicolai, Reimer Toralf, Schneeweiss Andreas, Schumacher-Wulf Eva, Schütz Florian, Thill Marc, Wuerstlein Rachel, Fasching Peter A, Kolberg-Liedtke Cornelia, Kolberg Hans-Christian, Thomssen Christoph, Bauerfeind Ingo, Braun Michael, Brucker Sara Y, Felberbaum Ricardo, Hagemann Friederike, Haidinger Renate, Hönig Arnd, Huober Jens, Jackisch Christian, Harbeck Nadia
Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
Kolberg H, Wallwiener M, Overkamp F, Tesch H, Ettl J, Luftner D, Müller V, Schütz F, Fasching P, Taran F, Hartkopf A, Janni W, Schneeweiss A, Fehm T, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux M, Brucker S. Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Frauenheilkd 2019; 79:470-482.
May 21, 2019Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
May 21, 2019Geburtshilfe Frauenheilkd 2019; 79:470-482
Kolberg Hans-Christian, Wallwiener Markus, Overkamp Friedrich, Tesch Hans, Ettl Johannes, Luftner Diana, Müller Volkmar, Schütz Florian, Fasching Peter A, Taran Florin-Andrei, Hartkopf Andreas D, Janni Wolfgang, Schneeweiss Andreas, Fehm Tanja N, Wöckel Achim, Huober Jens, Pontones Constanza, Titzmann Adriana, Belleville Erik, Lux Michael P, Brucker Sara Y
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
Untch M, Hackmann J, Blohmer J, Rhiem K, Schmitt W, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Hanusch C, Just M, Fasching P, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol 2019; 37:2226-2234.
May 13, 2019NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
May 13, 2019J Clin Oncol 2019; 37:2226-2234
Untch Michael, Hackmann John, Blohmer Jens-Uwe, Rhiem Kerstin, Schmitt Wolfgang D, Furlanetto Jenny, Gerber Bernd, Huober Jens, Nekljudova Valentina, von Minckwitz Gunter, Hanusch Claus, Just Marianne, Fasching Peter A, Jackisch Christian, Schneeweiss Andreas, Schmatloch Sabine, Aktas Bahriye, Denkert Carsten, Schem Christian, Wiebringhaus Hermann, Kümmel Sherko, Warm Mathias, Loibl Sibylle
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
Laakmann E, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Blohmer J, Zahm D, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res 2019; 21:60.
May 10, 2019Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
May 10, 2019Breast Cancer Res 2019; 21:60
Laakmann Elena, Ingold-Heppner Barbara, Huober Jens, Hanusch Claus, Jackisch Christian, Reinisch Mattea, Untch Michael, von Minckwitz Gunter, Nekljudova Valentina, Müller Volkmar, Blohmer Jens-Uwe, Zahm Dirk-Michael, Witzel Isabell, Fasching Peter A, Rezai Mahdi, Schem Christian, Solbach Christine, Tesch Hans, Klare Peter, Schneeweiss Andreas, Salat Christoph, Loibl Sibylle
Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases
de Gregorio N, de Gregorio A, Ebner F, Friedl T, Huober J, Hefty R, Wittau M, Janni W, Widschwendter P. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases. Arch Gynecol Obstet 2019; 300:161-168.
Apr 22, 2019Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases
Apr 22, 2019Arch Gynecol Obstet 2019; 300:161-168
de Gregorio N, de Gregorio A, Ebner F, Friedl T W P, Huober Jens, Hefty R, Wittau M, Janni W, Widschwendter P
Luminal Metastatic Breast Cancer
Huober J, Bartsch R, Marme F, Pagani O, Thomssen C. Luminal Metastatic Breast Cancer. Breast Care (Basel) 2019; 14:99-101.
Apr 9, 2019Luminal Metastatic Breast Cancer
Apr 9, 2019Breast Care (Basel) 2019; 14:99-101
Huober Jens, Bartsch Rupert, Marme Frederik, Pagani Olivia, Thomssen Christoph
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Rothé F, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson S, Chia S, Rosa D, Di Cosimo S, Silva M, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Ignatiadis M. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clin Cancer Res 2019; 25:3581-3588.
Mar 12, 2019Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Mar 12, 2019Clin Cancer Res 2019; 25:3581-3588
Rothé Françoise, Wardley Andrew, Ueno Takayuki, Janni Wolfgang, Huober Jens, Baselga José, Piccart Martine, Loi Sherene, Sotiriou Christos, Dawson Sarah-Jane, Chia Stephen, Rosa Daniela, Di Cosimo Serena, Silva Maria Joao, Venet David, Campbell Christine, Bradburry Ian, Rouas Ghizlane, de Azambuja Evandro, Maetens Marion, Fumagalli Debora, Rodrik-Outmezguine Vanessa, Ignatiadis Michail
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Di Cosimo S, Verderio P, Apolone G, de Braud F, Piccart M, Baselga J, Huober J, Izquierdo M, de la Pena L, de Azambuja E, Hilbers F, Iorio M, Tiberio P, Pizzamiglio S, Appierto V, Daidone M. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. Clin Cancer Res 2019; 25:3887-3895.
Feb 27, 2019Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Feb 27, 2019Clin Cancer Res 2019; 25:3887-3895
Di Cosimo Serena, Verderio Paolo, Apolone Giovanni, de Braud Filippo G, Piccart Martine, Baselga José, Huober Jens, Izquierdo Miguel, de la Pena Lorena, de Azambuja Evandro, Hilbers Florentine, Iorio Marilena V, Tiberio Paola, Pizzamiglio Sara, Appierto Valentina, Daidone Maria Grazia
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Hanker A, Castellino S, Joensuu H, Huober J, Brase J, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Groseclose M, Becker J, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, Langley E, Singh S, Kim P, Frampton G, Sanford E, Owens P, Arteaga C. Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2019; 25:1434.
Feb 15, 2019Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Feb 15, 2019Clin Cancer Res 2019; 25:1434
Hanker Ariella B, Castellino Stephen, Joensuu Heikki, Huober Jens, Brase Jan C, Majjaj Samira, Brohée Sylvain, Venet David, Brown David, Baselga José, Piccart Martine, Sotiriou Christos, Groseclose M Reid, Becker Jennifer, Garrett Joan T, Estrada Mónica Valeria, Moore Preston D, Ericsson Paula González, Koch James P, Langley Emma, Singh Sharat, Kim Phillip S, Frampton Garrett M, Sanford Eric, Owens Philip, Arteaga Carlos L
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Loibl S, Schmitt W, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, Grischke E, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019; 30:1279-1288.
Jan 1, 2019A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Jan 1, 2019Ann Oncol 2019; 30:1279-1288
Loibl S, Schmitt W D, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P A, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober Jens, Sinn B V, Blohmer J-U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Lux M, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Schneeweiss A, Belleville E, Beckmann M, Müller V, Nabieva N, Hartkopf A, Huober J, Volz B, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Brucker S. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers (Basel) 2018; 11
Dec 21, 2018Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Dec 21, 2018Cancers (Basel) 2018; 11
Lux Michael P, Wimberger Pauline, Hielscher Carsten, Geberth Matthias, Abenhardt Wolfgang, Kurbacher Christian, Wuerstlein Rachel, Thomssen Christoph, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Schneeweiss Andreas, Belleville Erik, Beckmann Matthias W, Müller Volkmar, Nabieva Naiba, Hartkopf Andreas D, Huober Jens, Volz Bernhard, Taran Florin-Andrei, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Luftner Diana, Wallwiener Markus, Brucker Sara Y
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Schneeweiss A, Ingold-Heppner B, Blohmer J, Rezai M, Frank M, Engels K, Rhiem K, Fasching P, Nekljudova V, von Minckwitz G, Thomalla J, Jackisch C, Kast K, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer 2018; 106:181-192.
Dec 5, 2018Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Dec 5, 2018Eur J Cancer 2018; 106:181-192
Schneeweiss Andreas, Ingold-Heppner Barbara, Blohmer Jens-Uwe, Rezai Mahdi, Frank Matthias, Engels Knut, Rhiem Kerstin, Fasching Peter Andreas, Nekljudova Valentina, von Minckwitz Gunter, Thomalla Jörg, Jackisch Christian, Kast Karin, Möbus Volker, Tesch Hans, Hanusch Claus, Denkert Carsten, Lübbe Kristina, Huober Jens, Klare Peter, Kümmel Sherko, Untch Michael, Loibl Sibylle
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
Bjelic-Radisic V, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Fasching P, Sinn H, Hirsmüller S, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Lux M, Harbeck N, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Nöthlings U, Müller V, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Möbus V, Stangl S, Paradies K, Wöckel A, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Kreienberg R, Kopp I, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann P, Jírů-Hillmann S, Albert U, Budach W, Follmann M, Janni W, Steckelberg A, Feyer P, Petersen C, Bartsch H, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Siedentopf F, Lebeau A, König K, Hahne A, Baumgartner T, Kreipe H, Knoefel W, Denkinger M, Brucker S, Luftner D, Kubisch C, Gerlach C, Honegger C. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:1056-1088.
Nov 26, 2018Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
Nov 26, 2018Geburtshilfe Frauenheilkd 2018; 78:1056-1088
Bjelic-Radisic Vesna, Dunst Jürgen, Münstedt Karsten, Bick Ulrich, Fallenberg Eva, Tholen Reina, Hung Roswita, Baumann Freerk, Beckmann Matthias W, Blohmer Jens, Fasching Peter, Sinn Hans-Peter, Hirsmüller Susanne, Degenhardt Friedrich, Wenz Frederik, Rick Oliver, Hölzel Dieter, Zaiss Matthias, Kemper Gudrun, Budach Volker, Denkert Carsten, Gerber Bernd, Tesch Hans, Lux Michael P, Harbeck Nadia, Schmidt Marcus, Schmutzler Rita, Schneeweiss Andreas, Schütz Florian, Stickeler Elmar, Thomssen Christoph, Untch Michael, Wesselmann Simone, Bücker Arno, Buck Andreas, Nöthlings Ute, Müller Volkmar, Hadji Peyman, Hauner Hans, Heywang-Köbrunner Sylvia, Huober Jens, Hübner Jutta, Jackisch Christian, Loibl Sibylle, Lück Hans-Jürgen, von Minckwitz Gunter, Möbus Volker, Stangl Stephanie, Paradies Kerstin, Wöckel Achim, Kühn Thorsten, Langer Thomas, Nothacker Monika, Scharl Anton, Schreer Ingrid, Link Hartmut, Engel Jutta, Fehm Tanja, Weis Joachim, Welt Anja, Kreienberg Rolf, Kopp Ina, Festl Jasmin, Stüber Tanja, Brust Katharina, Krockenberger Mathias, Heuschmann Peter U, Jírů-Hillmann Steffi, Albert Ute-Susann, Budach Wilfried, Follmann Markus, Janni Wolfgang, Steckelberg Anke, Feyer Petra, Petersen Cordula, Bartsch Hans Helge, Schulz-Wendtland Rüdiger, Hahn Markus, Hanf Volker, Müller-Schimpfle Markus, Henscher Ulla, Roncarati Renza, Katalinic Alexander, Heitmann Christoph, Siedentopf Friederike, Lebeau Annette, König Klaus, Hahne Andrea, Baumgartner Traudl, Kreipe Hans H, Knoefel Wolfram Trudo, Denkinger Michael, Brucker Sara, Luftner Diana, Kubisch Christian, Gerlach Christina, Honegger Christoph
Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years - Comparison of a University Center and a Community Hospital
De Gregorio A, Widschwendter P, Albrecht S, De Gregorio N, Friedl T, Huober J, Janni W, Ebner F. Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years - Comparison of a University Center and a Community Hospital. Geburtshilfe Frauenheilkd 2018; 78:1138-1145.
Nov 26, 2018Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years - Comparison of a University Center and a Community Hospital
Nov 26, 2018Geburtshilfe Frauenheilkd 2018; 78:1138-1145
De Gregorio Amelie, Widschwendter Peter, Albrecht Susanne, De Gregorio Nikolaus, Friedl Thomas W P, Huober Jens, Janni Wolfgang, Ebner Florian K
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Powles R, Pusztai L, Elemento O, Piccart-Gebhart M, Baselga J, Huober J, Di Cosimo S, Sarp S, de Azambuja E, Harbeck N, Nuciforo P, Fumagalli D, Loi S, Sotiriou C, Redmond D, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2018; 4:e181564.
Nov 8, 2018Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Nov 8, 2018JAMA Oncol 2018; 4:e181564
Powles Ryan L, Pusztai Lajos, Elemento Olivier, Piccart-Gebhart Martine, Baselga José, Huober Jens, Di Cosimo Serena, Sarp Severine, de Azambuja Evandro, Harbeck Nadia, Nuciforo Paolo, Fumagalli Debora, Loi Sherene, Sotiriou Christos, Redmond David, Hatzis Christos
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
Bjelic-Radisic V, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Sinn H, Hirsmüller S, Tesch H, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Fasching P, Lux M, Harbeck N, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Nöthlings U, Müller V, Möbus V, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Krockenberger M, Wöckel A, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Kühn T, Kreienberg R, Kopp I, Festl J, Stüber T, Brust K, Stangl S, Heuschmann P, Albert U, Budach W, Follmann M, Janni W, Steckelberg A, Feyer P, König K, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Bartsch H, Petersen C, Siedentopf F, Hahne A, Kreipe H, Knoefel W, Denkinger M, Brucker S, Luftner D, Kubisch C, Gerlach C, Lebeau A, Paradies K. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:927-948.
Oct 19, 2018Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
Oct 19, 2018Geburtshilfe Frauenheilkd 2018; 78:927-948
Bjelic-Radisic Vesna, Dunst Jürgen, Münstedt Karsten, Bick Ulrich, Fallenberg Eva, Tholen Reina, Hung Roswita, Baumann Freerk, Beckmann Matthias W, Blohmer Jens, Sinn Hans-Peter, Hirsmüller Susanne, Tesch Hans, Degenhardt Friedrich, Wenz Frederik, Rick Oliver, Hölzel Dieter, Zaiss Matthias, Kemper Gudrun, Budach Volker, Denkert Carsten, Gerber Bernd, Fasching Peter A, Lux Michael P, Harbeck Nadia, Schmidt Marcus, Schmutzler Rita, Schneeweiss Andreas, Schütz Florian, Stickeler Elmar, Thomssen Christoph, Untch Michael, Wesselmann Simone, Bücker Arno, Nöthlings Ute, Müller Volkmar, Möbus Volker, Hadji Peyman, Hauner Hans, Heywang-Köbrunner Sylvia, Huober Jens, Hübner Jutta, Jackisch Christian, Loibl Sibylle, Lück Hans-Jürgen, von Minckwitz Gunter, Krockenberger Mathias, Wöckel Achim, Langer Thomas, Nothacker Monika, Scharl Anton, Schreer Ingrid, Link Hartmut, Engel Jutta, Fehm Tanja, Weis Joachim, Welt Anja, Kühn Thorsten, Kreienberg Rolf, Kopp Ina, Festl Jasmin, Stüber Tanja, Brust Katharina, Stangl Stephanie, Heuschmann Peter U, Albert Ute-Susann, Budach Wilfried, Follmann Markus, Janni Wolfgang, Steckelberg Anke, Feyer Petra, König Klaus, Schulz-Wendtland Rüdiger, Hahn Markus, Hanf Volker, Müller-Schimpfle Markus, Henscher Ulla, Roncarati Renza, Katalinic Alexander, Heitmann Christoph, Honegger Christoph, Bartsch Hans Helge, Petersen Cordula, Siedentopf Friederike, Hahne Andrea, Kreipe Hans H, Knoefel Wolfram Trudo, Denkinger Michael, Brucker Sara, Luftner Diana, Kubisch Christian, Gerlach Christina, Lebeau Annette, Paradies Kerstin
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
Lambertini M, de Azambuja E, Gelber R, Piccart-Gebhart M, Moreno-Aspitia A, Baselga J, Huober J, Tenglin R, Di Cosimo S, Azim H, Korde L, Schuehly U, Hilbers F, Guillaume S, Campbell C, Martel S, Ignatiadis M. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer 2018; 125:307-316.
Oct 18, 2018Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
Oct 18, 2018Cancer 2018; 125:307-316
Lambertini Matteo, de Azambuja Evandro, Gelber Richard D, Piccart-Gebhart Martine, Moreno-Aspitia Alvaro, Baselga José, Huober Jens, Tenglin Richard C, Di Cosimo Serena, Azim Hatem A, Korde Larissa, Schuehly Uwe, Hilbers Florentine S, Guillaume Sébastien, Campbell Christine, Martel Samuel, Ignatiadis Michail
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
Fasching P, Huober J, Liedtke C, Weinshilboum R, Wang L, Ingle J, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, von Minckwitz G, Fehm T, Blohmer J, Costa S, Loibl S, Hu C, Hart S, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Couch F. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018; 36:2281-2287.
May 23, 2018BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
May 23, 2018J Clin Oncol 2018; 36:2281-2287
Fasching Peter A, Huober Jens, Liedtke Cornelia, Weinshilboum Richard M, Wang Liewei, Ingle James N, Müller Volkmar, Nekljudova Valentina, Weber Karsten E, Rack Brigitte, Rübner Matthias, von Minckwitz Gunter, Fehm Tanja, Blohmer Jens-Uwe, Costa Serban Dan, Loibl Sibylle, Hu Chunling, Hart Steven N, Shimelis Hermela, Moore Raymond, Schem Christian, Tesch Hans, Untch Michael, Hilfrich Jörn, Rezai Mahdi, Gerber Bernd, Couch Fergus J
Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Loibl S, Kronenwett R, von Minckwitz G, Staebler A, Müller V, Darb-Esfahani S, Hartmann A, Furlanetto J, Kümmel S, Pfitzner B, Engels K, Schem C, Marme F, Krappmann K, Huober J, Weber K, Denkert C. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clin Cancer Res 2018; 24:3358-3365.
Apr 4, 2018Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Apr 4, 2018Clin Cancer Res 2018; 24:3358-3365
Loibl Sibylle, Kronenwett Ralf, von Minckwitz Gunter, Staebler Annette, Müller Volkmar, Darb-Esfahani Silvia, Hartmann Arndt, Furlanetto Jenny, Kümmel Sherko, Pfitzner Berit Maria, Engels Knut, Schem Christian, Marme Frederik, Krappmann Kristin, Huober Jens, Weber Karsten, Denkert Carsten
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Untch M, Loibl S, Nekljudova V, Fehm T, Hauschild M, Blohmer J, Kunz G, Jackisch C, Solbach C, Huober J, Hanusch C, Eggemann H, Tesch H, Fasching P, Rezai M, Schem C, Gerber B, von Minckwitz G, GBG and the AGO-B Study Group. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol 2018; 36:1308-1316.
Mar 15, 2018Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Mar 15, 2018J Clin Oncol 2018; 36:1308-1316
Untch Michael, Loibl Sibylle, Nekljudova Valentina, Fehm Tanja, Hauschild Maik, Blohmer Jens-Uwe, Kunz Georg, Jackisch Christian, Solbach Christine, Huober Jens, Hanusch Claus, Eggemann Holm, Tesch Hans, Fasching Peter A, Rezai Mahdi, Schem Christian, Gerber Bernd, von Minckwitz Gunter, GBG and the AGO-B Study Group